Vectura and Philip Morris – the leopard hasn’t changed its spots.
File(s)
Accepted version
Author(s)
Hopkinson, Nicholas
Type
Journal Article
Abstract
The uniquely lethal nature of the tobacco industry’s products, the industry’s environmental impact and its incompatibility with human rights make the takeover of Vectura, a pharmaceutical company focused on inhaler technology, by tobacco giant Philip Morris International (PMI), extremely unwelcome. The idea that a company which, based on its market share and the global death toll, kills more than a million people every year4 should be allowed to expand into the delivery of healthcare has been widely condemned, including by the British Thoracic Society, the European Respiratory Society and the US COPD Foundation, as well as the American Lung Association and American Thoracic Society who referred to the move as “reprehensible”.
Date Issued
2022-05-17
Date Acceptance
2021-11-26
Citation
Thorax, 2022, 77 (6)
ISSN
0040-6376
Publisher
BMJ Publishing Group
Journal / Book Title
Thorax
Volume
77
Issue
6
Copyright Statement
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ. This article has been accepted for publication in Thorax following peer review. The definitive copyedited, typeset version Hopkinson NSVectura and Philip Morris: the leopard has not changed its spotsThorax 2022;77:537-538.
is available online at: http://dx.doi.org/10.1136/thoraxjnl-2021-218328
is available online at: http://dx.doi.org/10.1136/thoraxjnl-2021-218328
Identifier
https://thorax.bmj.com/content/77/6/537
Subjects
Science & Technology
Life Sciences & Biomedicine
Respiratory System
tobacco control
Humans
Smoking
Tobacco Industry
Humans
Smoking
Tobacco Industry
Respiratory System
1103 Clinical Sciences
Publication Status
Published
Date Publish Online
2021-12-23